EXPERIMENTAL IMMUNOLOGY
Staphylococcus enterotoxin B-induced T cells can efficaciously protect against type 1 diabetes in non-obese diabetic mice
Submission date: 2015-03-19
Final revision date: 2015-04-27
Acceptance date: 2015-05-26
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):292-299
KEYWORDS
immunomodulatorytype 1 diabetesStaphylococcus enterotoxin BCD8+ natural killer Ttransforming growth factor-βadoptive transfer
ABSTRACT
Type 1 diabetes (T1D), an autoimmune disease, can be protected against by natural killer T (NKT) cells. Several attempts demonstrate that NKT cells also can be produced by inducing with Staphylococcus enterotoxin B (SEB) in addition to its classical activated antigen -galactosylceramide. Here, we examined a potential usage of SEB-induced T (SEB-T) cells for the treatment of T1D. We established the immunophenotypes of SEB-T cells via flow cytometry, and in consequence, enriched in CD8+NKT cells after SEB stimulated. A high level of transforming growth factor β (TGF-β), detected by RT-PCR and ELISA, was first observed to be expressed and secreted by these SEB-T cells. Mixed lymphocyte reactions indicated that SEB-T cells could not produce a response to mitogens and allogeneic lymphocyte, and can inhibit lymphocytes response to mitogens. In an animal model, our data indicated that infusion of SEB-T cells in non-obese diabetic mice was well tolerated and could ameliorate hyperglycemia and maintain the blood glucose nearly on normal level until sacrifice. Strikingly, infusion of SEB-T cells resulted in an increase in the serum TGF-βlevel. These data raise the possibility that SEB-T cells can protect against T1D, which is associated with NKT cells generated in these SEB-induced cells.
REFERENCES (26)
1.
Stadinski B, Kappler J, Eisenbarth GS (2010): Molecular targeting of islet autoantigens. Immun 32: 446-456.
2.
Willcox A, Richardson SJ, Bone AJ, et al. (2009): Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155: 173-181.
3.
Li CR, Baaten BJ, Bradley LM (2012): Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. J Mol Cell Biol 4: 38-47.
4.
Hong S, Wilson MT, Serizawa I, et al. (2001): The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7: 1052-1056.
5.
Sharif S, Arreaza GA, Zucker P, et al. (2001): Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 7: 1057-1062.
6.
Taniguchi M (1999): V alpha 14 NKT cells as a novel immune system. Nihon Rinsho Meneki Gakkai Kaishi 22: 363-367.
7.
Seino K, Taniguchi M (2005): Functionally distinct NKT cell subsets and subtypes. J Exp Med 202: 1623.
8.
Chen YG, Choisy-Rossi CM, Holl TM, et al. (2005): Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 174: 1196-1204.
9.
Naumov YN, Bahjat KS, Gausling R, et al. (2001): Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A 98: 13838-13843.
10.
Zhou D, Mattner J, Cantu C 3rd, et al. (2004): Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789.
11.
Kinjo Y, Wu D, Kim G, et al. (2005): Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525.
12.
Chen G, Han G, Wang J, et al. (2008): Induction of active tolerance and involvement of CD1d-restricted natural killer T cells in anti-CD3 F(ab’)2 treatment-reversed new-onset diabetes in nonobese diabetic mice. Am J Pathol 172: 972-979.
13.
Kadri N, Korpos E, Gupta S, et al. (2012): CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol 188: 3138-3149.
14.
D'Alise AM, Ergun A, Hill JA, et al. (2011): A cluster of coregulated genes determines TGF-{beta}-induced regulatory T-cell (Treg) dysfunction in NOD mice. Proc Natl Acad Sci U S A 108: 8737-8742.
15.
Jansen A, Homo-Delarche F, Hooijkaas H, et al. (1994): Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 43: 667-675.
16.
Rajbhandary S, Zhao MF, Zhao N, et al. (2013): Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells Signaled through STAT-3 and STAT5b pathways. Asian Pac J Cancer Prev 14: 5825-5831.
17.
Zorena K, Malinowska E, Raczyńska D, et al. (2013): Serum concentrations of transforming growth factor-Beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. J Diabetes Res 2013: 614908.
18.
Ishigame H, Zenewicz LA, Sanjabi S, et al. (2013): Excessive Th1 responses due to the absence of TGF-β signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci USA 110: 6961-6966.
19.
Shull MM, Ormsby I, Kier AB, et al. (1992): Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
20.
Fantini MC, Becker C, Monteleone G, et al. (2004): Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149-5153.
21.
Cabrera SM, Rigby MR, Mirmira RG (2012): Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med 12: 1261-1272.
22.
Thomas DC, Wong FS, Zaccone P, et al. (2013): Protection of islet grafts through TGF beta induced tolerogenic DC. Diabetes 62: 3132-3142.
23.
Tang Q, Bluestone JA (2008): The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9: 239-244.
24.
Zhang H, Chua KS, Guimond M, et al. (2005): Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 11: 1238-1243.
25.
Wolf M, Schimpl A, Hünig T (2001): Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(–) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur J Immunol 31: 1637-1645.
26.
Duarte N, Stenström M, Campino S, et al. (2004): Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol 173: 3112-3118.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
